In this randomized controlled trial involving pediatric patients, fremanezumab led to greater reductions in the number of migraine days per month versus placebo, consistent with previous trials in ...

AJOVY demonstrated efficacy and a consistent safety profile in the SPACE trial, making it the first and only calcitonin gene-related peptide ...

PARSIPPANY, N.J. and TEL AVIV, Israel, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced today that the U.S. Food and ...

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announces new data from the 4th interim analysis of the PEARL migraine prevention study with AJOVY ® ...

SPACE pediatric Phase 3 study met its primary end point for efficacy with a significantly greater reduction in Monthly Migraine Days compared to placebo Efficacy is consistent with AJOVY (fremanezumab ...

Please provide your email address to receive an email when new articles are posted on . Ajovy offers “significant efficacy” compared with placebo to address episodic migraine in children and ...

The FDA expanded the indication for fremanezumab (Ajovy) injection for episodic migraine prevention to include children and adolescents, Teva Pharmaceuticals announced. Fremanezumab can now be used to ...

Teva Pharmaceutical (NYSE:TEVA) is one of the most undervalued large cap stocks to buy according to analysts. On June 24, Teva Pharmaceutical announced the final analysis results from its PEARL Phase ...